6 new oncology trials approved in Europe
 |
Oncology Hero |
6 new oncology trials approved in Europe
Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week.
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
| Sponsor: Oslo Universitetssykehus HF | Phase: Not specified |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator’s Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.
| Sponsor: Janssen Cilag International | Phase: Not specified |
Interested in offering this trial to suitable patients?
Register Investigator InterestMulticenter, open label, phase II clinical trial of inotuzumab ozogamicin as prophylaxis for relapse in patients with high-risk acute B-cell precursor acute lymphoblastic leukaemia after allogeneic stem cell haemotopoietic transplantation
| Sponsor: Fundacion PETHEMA | Phase: Not specified |
Interested in offering this trial to suitable patients?
Register Investigator InterestAn Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex®-C plus Standard Medical Treatment to Prevent Infections in Participants with Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma (Sigma).
| Sponsor: Grifols Therapeutics LLC | Phase: Not specified |
Interested in offering this trial to suitable patients?
Register Investigator InterestOptimization of De-EscalatiON strategies in early breast cancer (ODEON)
| Sponsor: Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS | Phase: Not specified |
Interested in offering this trial to suitable patients?
Register Investigator InterestRandomized phase 2 study of second-line chemotherapy comparing FOLFIRI + ivonescimab versus FOLFIRI + bevacizumab in Microsatellite Stable (MSS)/proficient MisMatch Repair (pMMR) BRAF wild type (wt) advanced colorectal cancer (mCRC) without liver metastases
| Sponsor: Unicancer | Phase: Not specified |
Interested in offering this trial to suitable patients?
Register Investigator InterestOncology Hero Trial Feed connects oncology professionals with relevant clinical trials.
For qualified healthcare and research professionals. Registration expresses investigator interest; it is not patient enrollment.
Oncology Hero
Sharing the latest updates in oncology
Oncology Hero 12 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials and investigator opportunities in Europe. EORTC-2456-LCG-BTG: A randomized phase II study evaluating upfront SRT to all brain metastases followed by ivonescimab plus chemotherapy versus upfront ivonescimab plus chemotherapy in patients with asymptomatic active brain metastases from NSCLC. Sponsor: European Organisation For Research And Treatment Of Cancer Phase:...
Oncology Hero 11 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe. A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients Sponsor: Centre Leon Berard Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest PD-1 blockade alone versus...
Oncology Hero 8 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe. Breast density reduction with linzagolix or bilastine in premenopausal women at high risk of breast cancer: a phase II clinical trial. Sponsor: Consorci Mar Parc De Salut De Barcelona Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest A phase 2 study to assess efficacy of induction...